Comparative Pharmacology
Head-to-head clinical analysis: DISPERMOX versus PENBRITIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISPERMOX versus PENBRITIN S.
DISPERMOX vs PENBRITIN-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Penicillinase-sensitive penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly/intravenously every 4-6 hours for moderate to severe infections.
None Documented
None Documented
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
0.5-1 hour; prolonged in renal impairment (up to 7-10 hours in anuria).
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Renal: 75-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic